Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.16%
#3 Velvet Velvet +44.46%
#4 Akedo Akedo +40.57%
#5 Black Phoenix Black Phoenix +33.98%
#6 Cross Cross +24.15%
#7 Cap Cap +20.35%
#8 DoubleZero DoubleZero +14.60%
#9 Tutorial Tutorial +11.59%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.77%
Coin of the day
Islamic Coin Islamic Coin
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
Clasificación en acciones #39467
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Precio por acción
$0.11725176
Última sincronización: 2025-07-14
Capitalización bursátil
$481.50K
Cambio (1 día)
-0.20%
Cambio (1 año)
0.00%
País
FR
Comercio PHAXIAM Therapeutics S.A. (PHXM)

Categoría

Healthcare
Ganancias de PHAXIAM Therapeutics S.A. (PHXM)
Ganancias en Jun 2024 TTM: $-23.51M
Secondo gli ultimi rapporti finanziari di PHAXIAM Therapeutics S.A., gli utili attuali della società sono $-23.51M. Nel 2022, la società ha registrato un utile di $-1.28M, un aumento con respecto a agli utili del 2021, che erano di $-65.34M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de PHAXIAM Therapeutics S.A. desde 2016 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-23.51M -14.00%
2023 $-27.34M 2,036.64%
2022 $-1.28M -98.04%
2021 $-65.34M -30.07%
2020 $-93.44M 25.10%
2019 $-74.70M 52.60%
2018 $-48.95M 11.10%
2017 $-44.06M 64.85%
2016 $-26.73M 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -22,533.08%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -8,395.72%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -12,882.70%
BE